Wu, X., Wang, J., Wang, D., Li, G., Zhang, J., Chen, H., Yang, H., Zhou, Q., Wang, K., Wu, Y., Yi, T., Liu, J., Huang, Y., Bai, Y., Wang, K., Jiang, K., Lou, H., An, R., Li, X., Pan, Y., Wang, Y., Tao, W., Song, K., Kang, Y., Li, Y., Shi, W., Liu, A., Yang, Y., Wang, Y., Chen, K., Shi, H., Lu, P., Tan, P., Fan, S., Shi, M., Su, W. (2025). Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial. Nature Communications. https://doi.org/10.1038/s41467-025-67375-3